Drug Trial Radar · NCT00456508
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Last checked: Nov 20, 2026Latest source record: Jun 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
147
Actual
Start
Apr 1, 2007
Primary completion
Jun 1, 2010
Study completion Sep 1, 2010
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Apr 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of repeated doses of ecallantide in the treatment of acute attacks of hereditary angioedema and to allow HAE patients continued access to ecallantide. In addition, patients enrolled in DX-88/20 (EDEMA4) trial will be followed up and treated for subsequent attacks in this trial.
Conditions
- Hereditary Angioedema (HAE)
Interventions
ecallantideDrug
solution for SC injection, one 30 mg dose per HAE attack
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hrs Post DosingTime frame: 4 hrs post dose after every episode
Locations
41 sites in 3 countries. Site status is shown where the registry gives one.
Aaron Davis
Scottsdale, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Little Rock Allergy & Asthma Clinic
Little Rock, Arkansas
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California
Pacific Coast Allergy
Crescent City, California
Jacob Offenberger
Granada Hills, California
UCLA David Geffen School of Medicine, Department of Medicine
Los Angeles, California
Asthma and Allergy Associates, P.C.
Colorado Springs, Colorado
Christiana Hospital, Christiana Care Health Services
Newark, Delaware
Georgetown University Medical Center, Georgetown University Hospital
Washington D.C., District of Columbia
University of Miami, General Clinical Research Center
Miami, Florida
University of South Florida, Asthma, Allergy and Immunology Clinical Research Unit
Tampa, Florida
Roberson Allergy and Asthma
West Palm Beach, Florida
Family Allergy & Asthma Center, PC
Atlanta, Georgia
Allergy Center of Brookstone
Columbus, Georgia
University Consultants in Allergy and Immunology
Chicago, Illinois
Muncie Allergy Center
Muncie, Indiana
Kansas City Allergy & Asthma
Overland Park, Kansas
Institute for Asthma and Allergy
Wheaton, Maryland
Brigham and Women's Hospital
Chestnut Hill, Massachusetts
Asthma and Allergy Institutes of Michigan
Clinton Township, Michigan
Respiratory Medicine Research Institute of Michigan, PLC
Ypsilanti, Michigan
Nevada Access to Research and Education Society
Las Vegas, Nevada
University of Nevada School of Medicine
Reno, Nevada
UMDNJ- New Jersey Medical School
Newark, New Jersey
Allergy Partners of Albuquerque
Albuquerque, New Mexico
Winthrop University Hospital
Mineola, New York
Allergy Partners of Western North Carolina
Asheville, North Carolina
University of Cincinnati, Division of Internal Medicine
Cincinnati, Ohio
Optimed Research, LLC
Columbus, Ohio
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania
Asthma Allergy and Pulmonary Associates
Philadelphia, Pennsylvania
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Highlands Allergy and Asthma Center, PC
Bristol, Tennessee
The Paull Allergy and Asthma Clinic, P.A
Bryan, Texas
AARA Research Center
Dallas, Texas
University of Utah Health Sciences Center
Salt Lake City, Utah
Clinical Research Associates of Tidewater
Norfolk, Virginia
Puget Sound Allergy, Asthma, & Immunology
Tacoma, Washington
Allergy and Asthma Research Centre
Ottawa, Ontario, Canada
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.